Akebia Strikes $350m+ Asian Vadadustat Alliance
This article was originally published in PharmAsia News
Mitsubishi Tanabe's agreement to acquire selected Asian rights to Akebia's vadadustat will boost the Japanese firm's existing presence in kidney disease while providing important funding for the US company's planned Phase III program with the novel anemia drug.
You may also be interested in...
Competition intensifies in novel anemia therapy space in Japan with first filing globally for Akebia/Mitsubishi Tanabe’s contender vadadustat, which could see its first launch worldwide in the country.
A licensing deal between the two cancer-focused biotechs falls apart amidst investor unrest at Immunomedics. Novartis opts to license Conatus' Phase II NASH candidate and picks up a CAR-T candidate from Celyad, while Shire adds to its dry eye franchise in deal with Parion.
Co-development deal worth $265m in near-term cash will allow Akebia to tap into Otsuka's established kidney disease infrastructure, while holding the reins on key aspects of commercialization.